Q1 EPS Estimates for DENTSPLY SIRONA Cut by Zacks Research

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) - Stock analysts at Zacks Research reduced their Q1 2025 earnings estimates for DENTSPLY SIRONA in a research note issued on Thursday, March 20th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will earn $0.31 per share for the quarter, down from their previous estimate of $0.42. The consensus estimate for DENTSPLY SIRONA's current full-year earnings is $1.84 per share. Zacks Research also issued estimates for DENTSPLY SIRONA's Q2 2025 earnings at $0.45 EPS, Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $1.81 EPS, Q1 2026 earnings at $0.34 EPS, Q2 2026 earnings at $0.48 EPS, Q3 2026 earnings at $0.49 EPS, Q4 2026 earnings at $0.58 EPS, FY2026 earnings at $1.89 EPS and FY2027 earnings at $2.19 EPS.

Several other equities research analysts have also recently issued reports on XRAY. Robert W. Baird cut their price target on DENTSPLY SIRONA from $22.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday, February 28th. Wells Fargo & Company cut their target price on DENTSPLY SIRONA from $20.00 to $19.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. UBS Group decreased their price target on DENTSPLY SIRONA from $35.00 to $27.00 and set a "buy" rating on the stock in a research report on Tuesday, December 3rd. Mizuho cut their price objective on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set a "neutral" rating for the company in a research report on Thursday, March 13th. Finally, Jefferies Financial Group downgraded shares of DENTSPLY SIRONA from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $30.00 to $20.00 in a research note on Thursday, January 23rd. Twelve equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $23.33.

Remove Ads

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY traded up $0.04 on Monday, reaching $15.64. 2,814,665 shares of the company's stock were exchanged, compared to its average volume of 3,002,910. DENTSPLY SIRONA has a twelve month low of $14.78 and a twelve month high of $33.42. The company has a fifty day moving average of $17.81 and a 200-day moving average of $20.33. The company has a market capitalization of $3.11 billion, a price-to-earnings ratio of -7.56, a PEG ratio of 1.80 and a beta of 0.98. The company has a current ratio of 1.25, a quick ratio of 0.84 and a debt-to-equity ratio of 0.72.

DENTSPLY SIRONA Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 11th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.09%. DENTSPLY SIRONA's payout ratio is presently -14.07%.

Insider Activity

In other DENTSPLY SIRONA news, Director Gregory T. Lucier acquired 15,142 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was acquired at an average price of $16.51 per share, for a total transaction of $249,994.42. Following the acquisition, the director now directly owns 81,971 shares in the company, valued at $1,353,341.21. This represents a 22.66 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.52% of the stock is owned by corporate insiders.

Institutional Trading of DENTSPLY SIRONA

Institutional investors and hedge funds have recently bought and sold shares of the stock. Natixis Advisors LLC lifted its holdings in DENTSPLY SIRONA by 21.1% in the third quarter. Natixis Advisors LLC now owns 21,733 shares of the medical instruments supplier's stock valued at $588,000 after buying an additional 3,787 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of DENTSPLY SIRONA by 50.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,065,773 shares of the medical instruments supplier's stock valued at $55,900,000 after purchasing an additional 692,100 shares during the period. Raymond James Trust N.A. boosted its position in shares of DENTSPLY SIRONA by 37.7% during the 3rd quarter. Raymond James Trust N.A. now owns 13,299 shares of the medical instruments supplier's stock valued at $360,000 after purchasing an additional 3,641 shares in the last quarter. Cerity Partners LLC acquired a new stake in DENTSPLY SIRONA during the third quarter worth approximately $482,000. Finally, QVIDTVM Management LLC lifted its stake in DENTSPLY SIRONA by 75.8% in the third quarter. QVIDTVM Management LLC now owns 458,866 shares of the medical instruments supplier's stock valued at $12,417,000 after buying an additional 197,803 shares during the period. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.